Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Head and Neck Pathology
Erschienen in: Head and Neck Pathology 1/2018

09.02.2018 | Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 18, 2018, Vancouver, British Columbia, Canada

Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma

verfasst von: Diana Bell

Erschienen in: Head and Neck Pathology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Sinonasal tumors with neuroendocrine differentiation form a group of rare heterogeneous neoplasms of neuroectodermal and epithelial origin, consisting of olfactory neuroblastomas and neuroendocrine carcinomas. Because the natural history and biological behavior of this group of tumors vary, the morphological diagnosis coupled with grading/staging is important for prognostication, and the approach to treatment and rehabilitation is multidisciplinary. The identification of molecular abnormalities underlying these tumors is critical to the development of specific targeted therapies and the design of clinical trials.
Literatur
1.
Bell D, Hanna EY, Weber RS, et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck. 2016;38(Suppl 1):E2259–66.CrossRefPubMed
2.
La Rosa S, Sessa F, Uccella S. Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol. 2016;27(4):284–311.CrossRefPubMed
3.
Uccella S, Ottini G, Facco C, et al. Neuroendocrine neoplasms of the head and neck and olfactory neuroblastoma. Diagnosis classification. Pathologica. 2017;109(1):14–30.PubMed
4.
Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2017;12(3):425–36.CrossRefPubMed
5.
La Rosa S, Furlan D, Franzi F, et al. Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinico-pathologic and molecular study of a case and review of the literature. Head Neck Pathol. 2013;7(1):76–84.CrossRefPubMed
6.
Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014;18(Suppl 2):S149–56.CrossRefPubMedPubMedCentral
7.
Thompson LDR, Bell D, Bishop JA. Neuroendocrine carcinomas. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of tumors of the head and neck. 4th ed. Tumors of the nasal cavity, paranasal sinuses and skull base. Lyon: IAC Press; 2017. pp. 21–3.
8.
Mitchell EH, Diaz A, Yilmaz T, et al. Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck. 2012;34(10):1372–6.CrossRefPubMed
9.
Mills SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol. 2002;15(3):264–78.CrossRefPubMed
10.
Rosenthal DI, Barker JL Jr, El-Naggar AK, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004;101(11):2567–73.CrossRefPubMed
11.
Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285–96.CrossRefPubMed
12.
Renner G. Small cell carcinoma of the head and neck: a review. Semin Oncol. 2007;34(1):3–14.CrossRefPubMed
13.
Babin E, Rouleau V, Vedrine PO, et al. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol. 2006;120(4):289–97.CrossRefPubMed
14.
Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94(10):2623–34.CrossRefPubMed
15.
van der Laan TP, Iepsma R, Witjes MJ, van der Laan BF, Plaat BE, Halmos GB. Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol. 2016;63:1–9.CrossRefPubMed
16.
Berger L, Luc R, Richard D. “L’esthesioneuroepitheliome Olfactif.” Bulletin de l’Association Fran?aise pour l’étude du Cancer.vol 13. 1924. pp. 410–21.
17.
Bell D, Franchi A, Gillison M, Thompson LDR, Wenig BM. Olfactory neuroblastoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of tumors of the head and neck. 4th ed. Tumors of the nasal cavity, paranasal sinuses and skull base. Lyon: IAC Press; 2017. pp. 57–9.
18.
Holmes M, Su SY, Bell D. Ectopic primary olfactory neuroblastoma of the maxillary sinus. Ann Diagn Pathol. 2016;22:45–8.CrossRefPubMed
19.
Ow TJ, Bell D, Kupferman ME, Demonte F, Hanna EY. Esthesioneuroblastoma. Neurosurg Clin N Am. 2013;24(1):51–65.CrossRefPubMed
20.
Faragalla H, Weinreb I. Olfactory neuroblastoma: a review and update. Adv Anat Pathol. 2009;16(5):322–31.CrossRefPubMed
21.
Holbrook EH, Wu E, Curry WT, Lin DT, Schwob JE. Immunohistochemical characterization of human olfactory tissue. Laryngoscope. 2011;121(8):1687–701.CrossRefPubMedPubMedCentral
22.
23.
Bell D, Saade R, Roberts D, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(1):51–9.CrossRefPubMed
24.
Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma - A population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 2007;133(3):276–80.CrossRefPubMed
25.
Platek ME, Merzianu M, Mashtare TL, et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol. 2011;6:41.CrossRefPubMedPubMedCentral
26.
Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37(3):1571–6.CrossRefPubMed
27.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32(5):706–14 (discussion 714–705).CrossRefPubMed
28.
Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 1992;102(8):843–9.CrossRefPubMed
29.
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRefPubMed
30.
Hyams VJ. Olfactory neuroblastoma (case 6). In: Batsakis JG, Hyams VJ, Morales AR, editors. Special tumors of the head and neck. Chicago: ASCP Press; 1982. pp. 24–9.
31.
Saade RE, Hanna EY, Bell D. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system. Curr Oncol Rep. 2015;17(1):423.CrossRefPubMed
32.
Kaur G, Kane AJ, Sughrue ME, et al. The prognostic implications of Hyam’s subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci. 2013;20(2):281–6.CrossRefPubMed
33.
Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer. 2013;49(6):1324–34.CrossRefPubMed
34.
Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival. J Neurol Surg Part B. 2012;73(5):331–6.CrossRef
35.
Mandarano M, Colella R, Giansanti M, Sidoni A. Aberrant pattern of cytokeratin expression in olfactory neuroblastoma: a potential diagnostic pitfall. Head Neck Pathol. 2017;11(2):262–3.CrossRefPubMed
36.
Singh L, Ranjan R, Madan R, Arava SK, Deepak RK, Singh MK. Microvessel density and Ki-67 labeling index in esthesioneuroblastoma: is there a prognostic role? Ann Diagn Pathol. 2015;19(6):391–6.CrossRefPubMed
37.
Turri-Zanoni M, Maragliano R, Battaglia P, et al. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol. 2017;74:21–9.CrossRefPubMed
38.
Thompson LD, Seethala RR, Muller S. Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immunophenotypic study of 32 cases with a comprehensive review of the english literature. Head Neck Pathol. 2012;6(1):75–100.CrossRefPubMedPubMedCentral
39.
Holland H, Koschny R, Krupp W, et al. Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet. 2007;173(2):89–96.CrossRefPubMed
40.
Bockmuhl U, You X, Pacyna-Gengelbach M, Arps H, Draf W, Petersen I. CGH pattern of esthesioneuroblastoma and their metastases. Brain Pathol. 2004;14(2):158–63.CrossRefPubMed
41.
Riazimand SH, Brieger J, Jacob R, Welkoborsky HJ, Mann WJ. Analysis of cytogenetic aberrations in esthesioneuroblastomas by comparative genomic hybridization. Cancer Genet Cytogenet. 2002;136(1):53–7.CrossRefPubMed
42.
Guled M, Myllykangas S, Frierson HF Jr, Mills SE, Knuutila S, Stelow EB. Array comparative genomic hybridization analysis of olfactory neuroblastoma. Mod Pathol. 2008;21(6):770–8.CrossRefPubMed
43.
Valli R, De Bernardi F, Frattini A, et al. Comparative genomic hybridization on microarray (a-CGH) in olfactory neuroblastoma: analysis of ten cases and review of the literature. Genes Chromosom Cancer. 2015;54(12):771–5.CrossRefPubMed
44.
Mao L, Xia YP, Zhou YN, et al. Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma. Oncology. 2009;77(3–4):231–43.CrossRefPubMed
45.
Gonzalez-Kristeller DC, Gutiyama LM, Campos AH, Soares FA, Brentani H, Malnic B. Odorant receptor genes are expressed in olfactory neuroblastoma. Genet Mol Res. 2013;12(3):3479–87.CrossRefPubMed
46.
Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci USA. 1993;90(12):5648–52.CrossRefPubMedPubMedCentral
47.
Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111(41):14788–93.CrossRefPubMedPubMedCentral
48.
Persson P, Jogi A, Grynfeld A, Pahlman S, Axelson H. HASH-1 and E2-2 are expressed in human neuroblastoma cells and form a functional complex. Biochem Biophys Res Commun. 2000;274(1):22–31.CrossRefPubMed
49.
Mhawech P, Berczy M, Assaly M, et al. Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract. Am J Clin Pathol. 2004;122(1):100–5.CrossRefPubMed
50.
Cordes B, Williams MD, Tirado Y, et al. Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. Hum Pathol. 2009;40(3):283–92.CrossRefPubMedPubMedCentral
51.
Taggart MW, Hanna EY, Gidley P, Weber RS, Bell D. Achaete-scute homolog 1 expression closely correlates with endocrine phenotype and degree of differentiation in sinonasal neuroendocrine tumors. Ann Diagn Pathol. 2015;19(3):154–6.CrossRefPubMed
52.
Gay LM, Kim S, Fedorchak K, et al. Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options. Oncologist. 2017;22(7):834–42.CrossRefPubMed
53.
Czapiewski P, Kunc M, Haybaeck J. Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment. Oncotarget. 2016;7(32):52584–96.CrossRefPubMedPubMedCentral
54.
Lazo de la Vega L, McHugh JB, Cani AK, et al. Comprehensive molecular profiling of olfactory neuroblastoma identifies potentially targetable FGFR3 amplifications. Mol Cancer Res. 2017;15(11):1551–7.CrossRef
55.
Ow TJ, Hanna EY, Roberts DB, et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck. 2014;36(4):524–30.CrossRefPubMed
56.
Venkatramani R, Pan H, Furman WL, et al. Multimodality treatment of pediatric esthesioneuroblastoma. Pediatr Blood Cancer. 2016;63(3):465–70.CrossRefPubMed
57.
Su SY, Bell D, Ferrarotto R, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017;39(8):1671–9.CrossRefPubMed
58.
Franchi A, Rocchetta D, Palomba A, Degli Innocenti DR, Castiglione F, Spinelli G. Primary combined neuroendocrine and squamous cell carcinoma of the maxillary sinus: report of a case with immunohistochemical and molecular characterization. Head Neck Pathol. 2015;9(1):107–13.CrossRefPubMed
Metadaten
Titel
Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma
verfasst von
Diana Bell
Publikationsdatum
09.02.2018
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 1/2018
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-018-0887-5

Weitere Artikel der Ausgabe 1/2018

Head and Neck Pathology 1/2018 Zur Ausgabe

Sine qua non Clinicopathologic Correlation

Angioleiomyoma (Vascular Leiomyoma) of the Oral Cavity

Original Paper

Can Medullary Thyroid Carcinoma Arise in Thyroglossal Duct Cysts? A Search for Parafollicular C-cells in 41 Resected Cases

Original Paper

Fibromyxoma of the Jaw: Case Report and Review of the Literature

Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 18, 2018, Vancouver, British Columbia, Canada

Human Papillomavirus-Related Neuroendocrine Carcinomas of the Head and Neck

Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 18, 2018, Vancouver, British Columbia, Canada

Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma—An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin

Original Paper

Squamous and Neuroendocrine Specific Immunohistochemical Markers in Head and Neck Squamous Cell Carcinoma: A Tissue Microarray Study

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Thiopental Originalie

Als Folge des Urteils des Bundesverfassungsgerichts zur Sterbehilfe im Jahr 2020 wurde in den Jahren 2021–2023 eine Reihe (n = 23) von assistierten Suiziden im Landesinstitut für gerichtliche und soziale Medizin Berlin mit jeweils identischen …

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …